{"url_path":"/sec/rzlt/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1509261/0001104659-26-059422-index.html","accession_number":"0001104659-26-059422","cik":"0001509261","ticker":"RZLT","issuer_name":"Rezolute, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1509261/0001104659-26-059422-index.html","primary_entity_key":"0001509261","primary_entity_name":"Rezolute, Inc."},"word_count":1254,"has_tables":true,"body_markdown":"REZOLUTE, INC._March 31, 2026\n\n0001509261--06-302026Q3falsehttp://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent0.250.278P10Y0.250.278P1Y10001509261us-gaap:CommonStockMember2026-01-012026-03-310001509261rzlt:PreFundedWarrants2025Member2026-01-012026-03-310001509261rzlt:PreFundedWarrants2024Member2026-01-012026-03-310001509261rzlt:PreFundedWarrants2022Member2026-01-012026-03-310001509261rzlt:PreFundedWarrants2021Member2026-01-012026-03-310001509261us-gaap:CommonStockMember2025-07-012026-03-310001509261rzlt:PreFundedWarrants2021Member2025-07-012026-03-310001509261us-gaap:CommonStockMember2025-01-012025-03-310001509261rzlt:PreFundedWarrants2024Member2025-01-012025-03-310001509261rzlt:PreFundedWarrants2022Member2025-01-012025-03-310001509261rzlt:PreFundedWarrants2021Member2025-01-012025-03-310001509261us-gaap:CommonStockMember2024-07-012025-03-310001509261rzlt:PreFundedWarrants2024Member2024-07-012025-03-310001509261rzlt:PreFundedWarrants2022Member2024-07-012025-03-310001509261rzlt:PreFundedWarrants2021Member2024-07-012025-03-310001509261rzlt:ExchangePreFundedWarrantsMember2024-07-012025-03-310001509261us-gaap:AdditionalPaidInCapitalMemberrzlt:PrivatePlacement2024Member2024-07-012025-03-310001509261rzlt:PrivatePlacement2024Member2024-07-012025-03-310001509261us-gaap:CommonStockMember2025-01-012025-03-310001509261us-gaap:CommonStockMember2026-01-012026-03-310001509261us-gaap:CommonStockMemberrzlt:PrivatePlacement2024Member2024-07-012025-03-310001509261us-gaap:EmployeeStockMember2025-07-012026-03-310001509261us-gaap:RetainedEarningsMember2026-03-310001509261us-gaap:AdditionalPaidInCapitalMember2026-03-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001509261us-gaap:RetainedEarningsMember2025-12-310001509261us-gaap:AdditionalPaidInCapitalMember2025-12-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-3100015092612025-12-310001509261us-gaap:RetainedEarningsMember2025-06-300001509261us-gaap:AdditionalPaidInCapitalMember2025-06-300001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001509261us-gaap:RetainedEarningsMember2025-03-310001509261us-gaap:AdditionalPaidInCapitalMember2025-03-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001509261us-gaap:RetainedEarningsMember2024-12-310001509261us-gaap:AdditionalPaidInCapitalMember2024-12-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-3100015092612024-12-310001509261us-gaap:RetainedEarningsMember2024-06-300001509261us-gaap:AdditionalPaidInCapitalMember2024-06-300001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001509261rzlt:PrivatePlacement2025Member2025-06-300001509261rzlt:UnderwrittenPublicOffering2025Member2025-04-240001509261rzlt:UnderwrittenOption2025Member2025-04-240001509261rzlt:PrivatePlacement2024Member2024-07-3100015092612025-11-190001509261srt:WeightedAverageMemberus-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-310001509261us-gaap:RestrictedStockUnitsRSUMember2025-06-300001509261srt:MaximumMemberrzlt:ChiefCommercialOfficerMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-08-012025-08-310001509261rzlt:ChiefCommercialOfficerMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-08-012025-08-310001509261rzlt:ChiefCommercialOfficerMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-08-012025-08-310001509261srt:MaximumMemberrzlt:EmployeesMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-07-012026-03-310001509261rzlt:EmployeesMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-07-012026-03-310001509261rzlt:EmployeesMemberrzlt:InducementGrantMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-07-012026-03-310001509261srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-310001509261srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-310001509261us-gaap:ResearchAndDevelopmentExpenseMember2025-10-012025-12-310001509261us-gaap:GeneralAndAdministrativeExpenseMember2025-10-012025-12-3100015092612025-10-012025-12-310001509261rzlt:PrivatePlacement2025Member2025-06-012025-06-300001509261rzlt:PrivatePlacement2024Member2024-07-012024-07-3100015092612025-12-152025-12-150001509261rzlt:Rz358Memberrzlt:SingleReportableSegmentMember2026-01-012026-03-310001509261rzlt:ResearchAndDevelopmentOtherExpenseMemberrzlt:SingleReportableSegmentMember2026-01-012026-03-310001509261rzlt:ResearchAndDevelopmentCompensationAndBenefitsExpenseMemberrzlt:SingleReportableSegmentMember2026-01-012026-03-310001509261rzlt:Rz358Memberrzlt:SingleReportableSegmentMember2025-07-012026-03-310001509261rzlt:ResearchAndDevelopmentOtherExpenseMemberrzlt:SingleReportableSegmentMember2025-07-012026-03-310001509261rzlt:ResearchAndDevelopmentCompensationAndBenefitsExpenseMemberrzlt:SingleReportableSegmentMember2025-07-012026-03-310001509261rzlt:Rz358Memberrzlt:SingleReportableSegmentMember2025-01-012025-03-310001509261rzlt:ResearchAndDevelopmentOtherExpenseMemberrzlt:SingleReportableSegmentMember2025-01-012025-03-310001509261rzlt:ResearchAndDevelopmentCompensationAndBenefitsExpenseMemberrzlt:SingleReportableSegmentMember2025-01-012025-03-310001509261rzlt:Rz358Memberrzlt:SingleReportableSegmentMember2024-07-012025-03-310001509261rzlt:ResearchAndDevelopmentOtherExpenseMemberrzlt:SingleReportableSegmentMember2024-07-012025-03-310001509261rzlt:ResearchAndDevelopmentCompensationAndBenefitsExpenseMemberrzlt:SingleReportableSegmentMember2024-07-012025-03-310001509261rzlt:PreFundedWarrants2025Memberrzlt:UnderwrittenPublicOffering2025Member2025-04-242025-04-240001509261us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2021-04-142021-04-140001509261rzlt:UnderwrittenOption2025Member2025-04-242025-04-2400015092612026-01-012026-01-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012026-03-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001509261us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012025-03-310001509261us-gaap:RetainedEarningsMember2026-01-012026-03-310001509261us-gaap:RetainedEarningsMember2025-07-012026-03-310001509261us-gaap:RetainedEarningsMember2025-01-012025-03-310001509261us-gaap:RetainedEarningsMember2024-07-012025-03-3100015092612024-07-012025-06-300001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2026-03-310001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2026-03-310001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2026-03-310001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2026-03-310001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2026-03-310001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2026-03-310001509261us-gaap:FinancialServicesSectorMember2026-03-310001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-06-300001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2025-06-300001509261rzlt:SingleReportableSegmentMember2026-01-012026-03-310001509261rzlt:SingleReportableSegmentMember2025-07-012026-03-310001509261rzlt:SingleReportableSegmentMember2025-01-012025-03-310001509261rzlt:SingleReportableSegmentMember2024-07-012025-03-310001509261us-gaap:EmployeeStockOptionMember2025-07-012026-03-310001509261rzlt:EmployeeStockOptionAndRestrictedStockUnitsRSUMember2025-07-012026-03-310001509261rzlt:EmployeeStockOptionAndRestrictedStockUnitsRSUMember2026-03-310001509261us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2026-03-310001509261us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-06-300001509261us-gaap:CommonStockMember2026-03-310001509261us-gaap:CommonStockMember2025-12-310001509261us-gaap:CommonStockMember2025-06-300001509261us-gaap:CommonStockMember2025-03-310001509261us-gaap:CommonStockMember2024-12-310001509261us-gaap:CommonStockMember2024-06-300001509261us-gaap:EmployeeStockMember2026-03-310001509261rzlt:PreFundedWarrantsMember2026-03-310001509261rzlt:PreFundedWarrants2025Member2026-03-310001509261rzlt:PreFundedWarrants2024Member2026-03-310001509261rzlt:PreFundedWarrants2022Member2026-03-310001509261rzlt:PreFundedWarrants2021Member2026-03-310001509261rzlt:PreFundedWarrantsMember2025-06-300001509261rzlt:PreFundedWarrants2025Member2025-06-300001509261rzlt:PreFundedWarrants2024Member2025-06-300001509261rzlt:PreFundedWarrants2022Member2025-06-300001509261rzlt:PreFundedWarrants2021Member2025-06-300001509261rzlt:PreFundedWarrantsMember2025-04-300001509261rzlt:PreFundedWarrants2025Memberrzlt:UnderwrittenPublicOffering2025Member2025-04-240001509261rzlt:LegacyWarrantsMember2025-06-300001509261rzlt:PreFundedWarrants2025Member2025-04-240001509261rzlt:PreFundedWarrants2024Member2024-06-300001509261rzlt:PreFundedWarrants2022Member2022-05-310001509261rzlt:PreFundedWarrants2021Member2021-10-310001509261rzlt:LegacyWarrantsMember2020-10-3100015092612025-03-3100015092612024-06-300001509261us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2026-03-310001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2026-03-310001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-06-300001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2025-06-300001509261us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2025-06-300001509261us-gaap:USTreasurySecuritiesMember2026-03-310001509261us-gaap:USTreasurySecuritiesMember2025-06-300001509261us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-06-300001509261us-gaap:CorporateDebtSecuritiesMember2026-03-310001509261us-gaap:CommercialPaperMember2026-03-310001509261us-gaap:CorporateDebtSecuritiesMember2025-06-300001509261us-gaap:CommercialPaperMember2025-06-300001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001509261us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001509261us-gaap:FairValueMeasurementsRecurringMember2026-03-310001509261us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001509261us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-06-300001509261us-gaap:FairValueMeasurementsRecurringMember2025-06-300001509261us-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-310001509261us-gaap:EmployeeStockOptionMember2025-07-012026-03-310001509261rzlt:LegacyWarrantsMember2025-07-012026-03-310001509261us-gaap:RestrictedStockUnitsRSUMember2024-07-012025-03-310001509261us-gaap:EmployeeStockOptionMember2024-07-012025-03-310001509261rzlt:LegacyWarrantsMember2024-07-012025-03-310001509261us-gaap:ResearchAndDevelopmentExpenseMember2026-01-012026-03-310001509261us-gaap:GeneralAndAdministrativeExpenseMember2026-01-012026-03-310001509261us-gaap:ResearchAndDevelopmentExpenseMember2025-07-012026-03-310001509261us-gaap:GeneralAndAdministrativeExpenseMember2025-07-012026-03-310001509261us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001509261us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-03-310001509261us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012025-03-310001509261us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012025-03-310001509261us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001509261us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100015092612025-01-012025-03-310001509261rzlt:SecuritiesExchangeAgreementMembersrt:MaximumMemberrzlt:PreFundedWarrantsMember2025-07-012026-03-310001509261us-gaap:AdditionalPaidInCapitalMember2025-07-012026-03-310001509261us-gaap:AdditionalPaidInCapitalMember2024-07-012025-03-310001509261us-gaap:CommonStockMember2025-07-012026-03-310001509261us-gaap:CommonStockMember2024-07-012025-03-310001509261rzlt:EmployeesMemberrzlt:InducementGrantMember2025-07-012026-03-310001509261rzlt:ChiefCommercialOfficerMemberrzlt:InducementGrantMember2025-08-012025-08-310001509261us-gaap:RestrictedStockUnitsRSUMember2026-03-310001509261us-gaap:EmployeeStockOptionMember2026-03-310001509261rzlt:Year2021PlanMember2026-03-310001509261rzlt:Year2019PlanMember2026-03-310001509261rzlt:Year2016PlanMember2026-03-310001509261rzlt:Year2015PlanMember2026-03-310001509261rzlt:InducementGrantMember2026-03-310001509261us-gaap:RestrictedStockUnitsRSUMember2025-07-012026-03-310001509261rzlt:AtMarketOfferingMember2025-10-012025-10-310001509261rzlt:AtMarketOfferingMember2023-11-142023-11-140001509261rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember2026-03-310001509261rzlt:HandokInc.Memberrzlt:HandokLicenseAgreementMemberus-gaap:RelatedPartyMember2020-09-152020-09-150001509261rzlt:UnderwrittenPublicOffering2025Member2025-04-242025-04-2400015092612024-07-012025-03-310001509261rzlt:ActivesitePharmaceuticalsIncMemberrzlt:ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember2026-03-310001509261rzlt:XomaUsLlcMemberrzlt:XomaLicenseAgreementMember2026-03-310001509261rzlt:XomaUsLlcMemberrzlt:ScenarioUponRegulatoryApprovalMemberrzlt:ClinicalTrialRz358Memberrzlt:XomaLicenseAgreementMember2025-07-012026-03-310001509261rzlt:ActivesitePharmaceuticalsIncMemberus-gaap:ScenarioPlanMemberrzlt:Phase3ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember2025-07-012026-03-310001509261rzlt:XomaUsLlcMemberrzlt:Phase3ClinicalTrialRz402Memberrzlt:XomaLicenseAgreementMember2025-06-012025-06-300001509261rzlt:ActivesitePharmaceuticalsIncMemberrzlt:Phase2ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember2023-02-012023-02-280001509261rzlt:XomaUsLlcMembersrt:MaximumMemberrzlt:ScenarioAfterClinicalAndRegulatoryMilestonesMemberrzlt:XomaLicenseAgreementMember2026-03-310001509261rzlt:ActivesitePharmaceuticalsIncMembersrt:MaximumMemberrzlt:ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember2026-03-310001509261rzlt:ActivesitePharmaceuticalsIncMemberus-gaap:ScenarioPlanMemberrzlt:ClinicalTrialRz402Memberrzlt:DevelopmentAndLicenseAgreementMember2017-08-012017-08-310001509261us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2021-04-140001509261rzlt:PreFundedWarrantsMember2025-07-012026-03-310001509261rzlt:PreFundedWarrants2025Member2025-07-012026-03-310001509261rzlt:PreFundedWarrants2024Member2025-07-012026-03-310001509261rzlt:PreFundedWarrants2022Member2025-07-012026-03-310001509261rzlt:LegacyWarrantsMember2025-07-012026-03-310001509261rzlt:LegacyWarrantsMember2026-03-3100015092612026-03-3100015092612025-06-3000015092612026-01-012026-03-3100015092612026-05-0800015092612025-07-012026-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purerzlt:planrzlt:subsidiaryrzlt:employeerzlt:segment\n\n[Table of Contents](#TOC)\n\n​\n\n​\n\n​\n\n​\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM ****10****-****Q**\n\n​\n\n**☒****QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the quarterly period ended****March 31, 2026**\n\n**or**\n\n**☐****TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n​\n\n**For the transition period from              to**\n\n**Commission File Number:****001-39683**\n\n​\n\n**REZOLUTE, INC.**\n\n(Exact Name of Registrant as Specified in its Charter)\n\n​\n\n​\n\n​\n\n​\n\n**Nevada**\n\n​\n\n**27-3440894**\n\n(State or other jurisdiction of incorporation or organization)\n\n​\n\n(I.R.S. Employer Identification No.)\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**275 Shoreline Drive, Suite 500****,****Redwood City****,****California**\n\n​\n\n**94065**\n\n(Address of principal executive offices)\n\n​\n\n(Zip Code)\n\n​\n\n**(****650****)****206-4507**\n\n(Registrant’s telephone number, including area code)\n\n**Not Applicable**\n\n(Former name, former address and former fiscal year, if changed since last report)\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n​\n\nTitle of each class\n\n  ​ ​ ​\n\nTrading Symbol(s)\n\n  ​ ​ ​\n\nName of each exchange on which registered\n\nCommon Stock, par value $0.001 per share\n\n​\n\nRZLT\n\n​\n\nNasdaq Capital Market\n\n​\n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No\n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.). ☒ Yes ☐ No\n\nIndicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, and an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n​\n\nLarge accelerated filer  ☐\n\nAccelerated filer  ☐\n\n \n\n \n\nNon-accelerated filer  ☒\n\nSmaller reporting company ☒\n\n \n\n \n\n \n\nEmerging growth company  ☐\n\n​\n\nIf an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 17(a)(2)(B) of the Securities Act. ☐\n\nIndicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ Yes ☒ No\n\nThe registrant had 96,292,331 shares of its $0.001 par value common stock outstanding as of May 8, 2026.\n\n​\n\n​\n\n​\n\n[Table of Contents](#TOC)\n\nTable of Contents\n\n​\n\n**Page**\n\n[PART I – FINANCIAL INFORMATION](#PARTIFINANCIALINFORMATION_968232)\n\n​\n\n​\n\n​\n\n[Item 1. Financial Statements](#ITEM1FINANCIALSTATEMENTS_900642)\n\n​\n\n[Unaudited Condensed Consolidated Balance Sheets – as of March 31, 2026 and June 30, 2025](#UnauditedCondensedConsolidatedBalanceShe)\n\n1\n\n[Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss – Three and Nine Months Ended March 31, 2026 and 2025](#StatementsofOperations_250178)\n\n2\n\n[Unaudited Condensed Consolidated Statements of Shareholders’ Equity – Nine Months Ended March 31, 2026 and 2025](#tatementsofStockholdersEquity_779103)\n\n3\n\n[Unaudited Condensed Consolidated Statements of Cash Flows – Nine Months Ended March 31, 2026 and 2025](#CashFlows_779261)\n\n4\n\n[Notes to Unaudited Condensed Consolidated Financial Statements](#NOTE1NATUREOFOPERATIONSANDSUMMARYOFSIGNF)\n\n5\n\n[Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations](#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF)\n\n21\n\n[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur)\n\n32\n\n[Item 4. Controls and Procedures](#Item4ControlsandProcedures_168243)\n\n32\n\n​\n\n​\n\n[PART II – OTHER INFORMATION](#PARTIIOTHERINFORMATION_207362)\n\n​\n\n​\n\n​\n\n[Item 1. Legal Proceedings](#Item1LegalProceedings_482523)\n\n33\n\n[Item 1A. Risk Factors](#Item1ARiskFactors_408641)\n\n33\n\n[Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities)\n\n33\n\n[Item 3. Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_240531)\n\n33\n\n[Item 4. Mine Safety Disclosures](#Item4MineSafetyDisclosures_633154)\n\n33\n\n[Item 5. Other Information](#Item5OtherInformation_954689)\n\n33\n\n[Item 6. Exhibits](#Item6Exhibits_624589)\n\n34\n\n​\n\n​\n\n[Signatures](#SIGNATURES_678092)\n\n35\n\n​\n\n​\n\n​\n\ni\n\n[Table of Contents](#TOC)\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS\n\nThis Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 (this “Report”) contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including, but not limited to “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as “anticipate”, “believe”, “estimate”, “expect”, “forecast”, “may”, “should”, “plan”, “project” and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:\n\n●our ability to obtain regulatory approvals for our therapeutics in development;\n\n●our expectations regarding clinical development and the timeline to complete clinical studies;\n\n●our projected operating or financial results, including anticipated cash flows to be used in operating activities;\n\n●our expectations regarding capital expenditures, research and development (“R&D”) expenses and the timing of milestone payments required under license agreements;\n\n●our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;\n\n●our future dependence on third-party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval; and\n\n●our ability to identify strategic partners and enter into license, co-development, collaboration or similar arrangements.\n\nAny or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known and unknown risks, uncertainties and other factors including, but not limited to, the risks described in Part II, Item 1A. Risk Factors, of this Report as well as “Risk Factors” described in (i) Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K”), filed with the Securities and Exchange Commission (“SEC”) on September 17, 2025 and (ii) in Part II, Item 1A of our Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2025 filed with the SEC on February 12, 2026.\n\nIn addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this Report, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Many of these factors will be important in determining our future results. Consequently, no forward-looking statement can be guaranteed. Our future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this Report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this Report, except as otherwise required by applicable law.\n\n​\n\n​\n\nii\n\n[Table of Contents](#TOC)\n\nPART I – FINANCIAL INFORMATION"}